[go: up one dir, main page]

MX2014000066A - Formulaciones mucoadhesivas en gel de alta dosificación de metronidazol de base acuosa y su uso para tratar la vaginosis bacteriana. - Google Patents

Formulaciones mucoadhesivas en gel de alta dosificación de metronidazol de base acuosa y su uso para tratar la vaginosis bacteriana.

Info

Publication number
MX2014000066A
MX2014000066A MX2014000066A MX2014000066A MX2014000066A MX 2014000066 A MX2014000066 A MX 2014000066A MX 2014000066 A MX2014000066 A MX 2014000066A MX 2014000066 A MX2014000066 A MX 2014000066A MX 2014000066 A MX2014000066 A MX 2014000066A
Authority
MX
Mexico
Prior art keywords
bacterial vaginosis
metronidazol
water based
high dosage
treat bacterial
Prior art date
Application number
MX2014000066A
Other languages
English (en)
Other versions
MX381271B (es
Inventor
Michael T Nordsiek
Kodumudi S Balaji
Original Assignee
Medicis Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47391265&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2014000066(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Medicis Pharmaceutical Corp filed Critical Medicis Pharmaceutical Corp
Publication of MX2014000066A publication Critical patent/MX2014000066A/es
Publication of MX381271B publication Critical patent/MX381271B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente descripción proporciona formulaciones de gel mucoadhesivo de base acuosa de metronidazol útiles para una variedad de propósitos, incluyendo la aplicación intravaginal como un abordaje terapéutico para el tratamiento de individuos que padecen y/o a los que se les diagnosticó vaginosis bacteriana.8.
MX2014000066A 2011-06-28 2012-06-28 Formulaciones mucoadhesivas en gel de alta dosificación de metronidazol de base acuosa y su uso para tratar la vaginosis bacteriana MX381271B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161502285P 2011-06-28 2011-06-28
US201161508058P 2011-07-14 2011-07-14
PCT/US2012/044738 WO2013003646A1 (en) 2011-06-28 2012-06-28 High dosage mucoadhesive metronidazole aqueous-based gel formulations their use to treat bacterial vaginosis

Publications (2)

Publication Number Publication Date
MX2014000066A true MX2014000066A (es) 2014-05-01
MX381271B MX381271B (es) 2025-03-11

Family

ID=47391265

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014000066A MX381271B (es) 2011-06-28 2012-06-28 Formulaciones mucoadhesivas en gel de alta dosificación de metronidazol de base acuosa y su uso para tratar la vaginosis bacteriana

Country Status (9)

Country Link
US (4) US8946276B2 (es)
EP (1) EP2725904B1 (es)
JP (2) JP5986632B2 (es)
CN (2) CN103763925A (es)
AU (2) AU2012275292B2 (es)
BR (1) BR112013033759B1 (es)
CA (2) CA3054236A1 (es)
MX (1) MX381271B (es)
WO (1) WO2013003646A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA115876C2 (uk) 2012-06-13 2018-01-10 Івофем, Інк. Композиція і спосіб підвищення ефективності бактерицидних засобів контрацепції
US9446024B2 (en) 2013-06-25 2016-09-20 UNIVERSITé LAVAL Formulations for the treatment of vaginal disorders
DK3082826T3 (da) 2013-12-19 2020-05-04 Evofem Inc Sammensætninger og fremgangsmåder til at inhibere inflammation og sygdomme under anvendelse af en alginsyre-baseret antimikrobiel forbindelse
CA2959414C (en) 2014-09-05 2023-03-14 Symbiomix Therapeutics, Llc Secnidazole for use in the treatment of bacterial vaginosis
WO2016196653A1 (en) 2015-06-01 2016-12-08 Symbiomix Therapeutics, Llc Novel nitroimidazole formulations and uses thereof
WO2017165836A1 (en) * 2016-03-24 2017-09-28 Rutgers, The State University Of New Jersey Antibacterial agents
CN110225750A (zh) * 2016-10-04 2019-09-10 伊沃菲姆股份有限公司 细菌性阴道病的治疗和预防方法
SE1750680A1 (en) * 2017-05-30 2018-12-01 Peptonic Medical Ab Composition for treating or preventing climacteric disorders
US20200126094A1 (en) * 2018-10-19 2020-04-23 BioIDC, Inc. Medical research fraud detection system and software
US12280037B2 (en) 2020-09-22 2025-04-22 Evofem Biosciences, Inc. Method and pharmaceutical composition for treating or preventing trichomoniasis and uses thereof

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4837378A (en) 1986-01-15 1989-06-06 Curatek Pharmaceuticals, Inc. Topical metronidazole formulations and therapeutic uses thereof
WO1988006888A1 (en) 1987-03-20 1988-09-22 Curatek Pharmaceuticals, Inc. Novel topical metronidazole formulations and therapeutic uses thereof
US5536743A (en) 1988-01-15 1996-07-16 Curatek Pharmaceuticals Limited Partnership Intravaginal treatment of vaginal infections with buffered metronidazole compositions
CA1337279C (en) 1989-06-06 1995-10-10 Robert J. Borgman Intravaginal treatment of vaginal infections with buffered metronidazole compositions
DE69201547T2 (de) 1991-10-18 1995-08-03 Dow Corning Silikon druckempfindliche Klebstoffe mit verbesserter Haftung an Substraten mit niedriger Oberflächenspannung.
IT1284874B1 (it) 1996-08-02 1998-05-22 Farmigea Spa Complessi bioadesivi di polycarbophil e farmaci antifungini o antiprotozoari azolici
GB9626513D0 (en) 1996-12-20 1997-02-05 Bioglan Ireland R & D Ltd A pharmaceutical composition
DE69819748T2 (de) 1997-09-12 2004-09-30 Columbia Laboratories (Bermuda) Ltd. Arzneimittel zur behandlung von dysmenorrhöe und verfrühten wehen
WO1998014768A2 (en) 1997-10-06 1998-04-09 Schwartz Sorell L Transdermal chemical monitoring device
US6468989B1 (en) * 2000-07-13 2002-10-22 Dow Pharmaceutical Sciences Gel compositions containing metronidazole
US6881726B2 (en) 2001-12-24 2005-04-19 Dow Pharmaceutical Sciences Aqueous compositions containing metronidazole
US7368122B1 (en) 2002-03-08 2008-05-06 Dow Pharmaceutical Sciences Skin cream
US9211259B2 (en) 2002-11-29 2015-12-15 Foamix Pharmaceuticals Ltd. Antibiotic kit and composition and uses thereof
US7704518B2 (en) 2003-08-04 2010-04-27 Foamix, Ltd. Foamable vehicle and pharmaceutical compositions thereof
US20050186142A1 (en) 2002-10-25 2005-08-25 Foamix Ltd. Kit and composition of imidazole with enhanced bioavailability
US7456207B2 (en) * 2003-09-25 2008-11-25 Teva Pharmaceuticals Usa, Inc. Vaginal pharmaceutical compositions and methods for preparing them
FR2887149B1 (fr) 2005-06-17 2007-08-03 Galderma Sa Procede de solubilisation du metronidazole
US20060093675A1 (en) * 2004-10-29 2006-05-04 Mathew Ebmeier Intravaginal treatment of vaginal infections with metronidazole compositions
FR2882552B1 (fr) 2005-02-25 2008-12-26 Galderma Sa Gel aqueux de haute stabilite a base de metronidazole et procedes pour leur preparation
CA2610662A1 (en) 2005-05-09 2007-05-18 Foamix Ltd. Foamable vehicle and pharmaceutical compositions thereof
EP1919449A2 (en) 2005-06-07 2008-05-14 Foamix Ltd. Antibiotic kit and composition and uses thereof
FR2890560B1 (fr) 2005-09-13 2011-06-24 Galderma Sa Mousses dermatologiques a base de metronidazole et emulsions pour leur preparation
FR2890559B1 (fr) 2005-09-13 2011-06-24 Galderma Sa Mousses dermatologiques a base de metronidazole et emulsions pour la preparation
WO2007086978A2 (en) 2005-11-09 2007-08-02 Dow Pharmaceutical Sciences Azithromycin for treatment of granulomatous rosacea
KR20080091793A (ko) 2006-01-05 2008-10-14 드러그테크 코포레이션 조성물 및 그것의 사용 방법
FR2899475A1 (fr) 2006-04-10 2007-10-12 Galderma Res & Dev Composition pharmaceutique pour le traitement de la rosacee
EP2029106A2 (en) 2006-06-07 2009-03-04 Foamix Ltd. Foamable vehicle comprising polypropylene glycol alkyl ether and pharmaceutical compositions thereof
US20080287514A1 (en) 2007-05-14 2008-11-20 Jerry Zhang Topical compositions containing metronidazole
US20080287513A1 (en) 2007-05-14 2008-11-20 Jerry Zhang Topical compositions containing metronidazole
US20080287515A1 (en) * 2007-05-14 2008-11-20 Jerry Zhang Topical compositions containing metronidazole
US20080312304A1 (en) 2007-06-13 2008-12-18 Jerry Zhang Topical compositions containing metronidazole
US7893097B2 (en) * 2008-02-02 2011-02-22 Dow Pharmaceutical Sciences, Inc. Methods and compositions for increasing solubility of azole drug compounds that are poorly soluble in water
US20100105750A1 (en) 2008-10-23 2010-04-29 Nycomed Us Inc. Stable metronidazole gel formulations
JP2013521300A (ja) 2010-03-03 2013-06-10 ネオキュティス エスアー 抗菌ペプチド隔離化合物を用いた皮膚疾患および皮膚障害の処置のための組成物および方法

Also Published As

Publication number Publication date
AU2012275292A1 (en) 2014-01-23
AU2012275292B2 (en) 2015-11-12
WO2013003646A1 (en) 2013-01-03
AU2016200825B2 (en) 2017-10-26
US20130005785A1 (en) 2013-01-03
US9198858B2 (en) 2015-12-01
BR112013033759A8 (pt) 2018-07-31
CN107823123A (zh) 2018-03-23
US8946276B2 (en) 2015-02-03
AU2016200825A1 (en) 2016-03-03
US10238634B2 (en) 2019-03-26
CA2840571A1 (en) 2013-01-03
BR112013033759A2 (pt) 2016-08-16
MX381271B (es) 2025-03-11
JP5986632B2 (ja) 2016-09-06
JP2014518272A (ja) 2014-07-28
US10596155B2 (en) 2020-03-24
US20160106714A1 (en) 2016-04-21
US20190183859A1 (en) 2019-06-20
CA2840571C (en) 2020-03-24
BR112013033759B1 (pt) 2021-05-25
JP6235087B2 (ja) 2017-11-22
EP2725904A1 (en) 2014-05-07
EP2725904A4 (en) 2014-12-10
CN103763925A (zh) 2014-04-30
EP2725904B1 (en) 2024-12-11
US20130005787A1 (en) 2013-01-03
CA3054236A1 (en) 2013-01-03
JP2017014248A (ja) 2017-01-19

Similar Documents

Publication Publication Date Title
MX2014000066A (es) Formulaciones mucoadhesivas en gel de alta dosificación de metronidazol de base acuosa y su uso para tratar la vaginosis bacteriana.
NI201500059A (es) Inhibidores de la tirosina-quinasa de bruton
CL2013000018A1 (es) Compuestos derivados de indolizina , su procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento del cancer, entre otros.
UY34278A (es) Derivados novedosos de oxazina y su uso en el tratamiento de enfermedades
CL2009000447A1 (es) Compuestos derivados de (1h-pirrolo{2,3-b}piridin-5-il)-sulfonamido-benzamida sustituida; procedimiento de preparacion; composicion farmaceutica; y su uso en el tratamiento del cancer, a travez de la inhibicion de raf.
UY32882A (es) (heteroarilmetil) tiohidantoínas sustituidas
UY33396A (es) 5-fluoro-1h-pirazolopiridinas sustituidas y su uso
MX2008016453A (es) Composiciones y metodos para tratar infecciones parasitas.
ECSP11011459A (es) Composiciones sublinguales de dexmedetomidina y métodos de uso de ellas
NI201500067A (es) Compuestos de pirrolopirimidina como inhibidores de quinasa
CL2013000016A1 (es) Compuestos derivados de imidazopiridina; procedimiento de preparacion; composicion farmaceutica y su uso en el tratamiento del cancer.
CR20120591A (es) Derivados de aminopirimidina como moduladores de la lrrk2
NI201300119A (es) Uso del anticuerpo anti - cd19 inmunoconjugado con maitansinoide para el tratatamiento del síntoma tumores de células b.
AR089993A1 (es) Macrociclos peptidomimeticos
CO6751287A2 (es) Composición antigénetica de micobacteria
CL2008001633A1 (es) Compuestos derivados de pirrolidin-3-carboxamida; composición farmacéutica; y uso comominhibidores de erk para el tratamiento del cancer.
CL2011003160A1 (es) Compuestos derivados de heterociclicos, moduladores cb2; composicion farmaceutica que los comprende; y uso en el tratamiento de enfermedades reumaticas, autoinmune, inflamatorias, dolor, entre otras.
NI201000044A (es) Bromhidrato de bupropión y aplicaciones terapéuticas
CL2008001373A1 (es) Compuestos derivados de fenilamino-benceno sustituidos; metodo de preparacion; composicion farmaceutica; kit farmceuticos; y uso de dichos compuestos en el tratamiento del cancer.
CR20110553A (es) Terapia complementaria contra el cáncer
CR20110318A (es) Compuestos, composición farmacéutica y métodos para utilizarse en el tratamiento de trastornos metabólicos
MX361778B (es) Composiciones farmaceuticas y metodos de tratamiento.
BR112012027197A2 (pt) combinação ou composição farmacêutica, seu uso, kit, e compostos para tratamento de doenças oncológicas e fibróticas
CL2012002887A1 (es) Combinación farmacéutica que comprende compuestos derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituida, compuestos derivados de n-(2-arilamino)arilsulfonamida y opcionalmente otros agentes farmacéuticos adicionales; kit faramacéutico; método de tratamiento; y su uso para el tratamiento o la profilaxis del cáncer.
CL2012001757A1 (es) Compuestos derivados de 8-hidroxiquinolina-7-carboxamida; composicion farmaceutica; y su uso en el tratamiento de infecciones micoticas.